$ONCO

Onconetix Inc. (NASDAQ: ONCO) stock rose 14.58% on news of its AI robotics deal with Realbotix, backed by SRX Global. The company's stock has been volatile, trading between $0.64 and $1.40 recently. ONCO has small revenue ($0.8M) and steep losses but holds $5.9M in cash. The Realbotix acquisition aims to pivot into AI and defense sectors, with a pilot project underway. ONCO provided $2.5M in bridge financing, with a 12% interest penalty if the deal fails.

ADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.

Onconetix Inc. (NASDAQ: ONCO) shares rose 19.69% after positive oncology trial results and an AI robotics deal. The company is acquiring Realbotix LLC, an AI-powered humanoid robot developer, in an all-stock transaction. ONCO provided $2.5M in bridge financing, with potential for $5M total. The company has minimal revenue ($0.82M) and negative net margins, but low debt and a high current ratio. Traders are watching the Realbotix pivot and potential Nasdaq uplisting.

Onco-Innovations (ONCO, ONNVF) and Redwood AI (AIRX, RDWCF) received a Digital Health Innovation Fund grant for their AI-driven oncology platform, SynoGraph. The grant covers up to 25% of the $3.5M project budget. The companies will collaborate with academic partners to advance the platform using federated learning and causal AI.

Oncopeptides AB (ONCO) announced that the CHMP recommended expanding Pepaxti's indication to third-line treatment for multiple myeloma, potentially doubling its addressable patient population. The European Commission will decide within 30-60 days. The company expects this to unlock commercial opportunities and support cash-flow positivity in 2027.

Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Filed by Onconetix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Onconetix, Inc. Commission File No.: 001-41294 Date: September 14,2026 Onconetix Provi

Onconetix, Inc. (ONCO) announced that Realbotix LLC, its pending acquisition target, has launched a pilot program with a European telecom firm to deploy AI-powered humanoid robots in live events. The pilot will evaluate robots' ability to present, host, and engage with audiences. Onconetix aims to complete the acquisition in the second half of 2026, subject to approvals. ONCO stock is currently at $0.70, up 3.86%.

Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”

Onco-Innovations Limited said it signed a services agreement with Nanosoft Polymers to support development of ONC010, its lead nanoparticle-formulated PNKP inhibitor. Nanosoft will handle polymer process development, analytical characterization, scale-up, formulation optimization and technology transfer for Onco’s PEO-PBCL platform, aiming to strengthen IND-enabling CMC and future GMP readiness.

Onconetix (NASDAQ: ONCO) announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. This split will reduce outstanding shares from approximately 11.4 million to 1.14 million, with fractional shares being cashed out. Historically, such reverse splits by Onconetix have been followed by negative market reactions, signaling investor caution.